drugset / Trial / NCT01878526

Gastroesophageal Reflux Treatment in Scleroderma

NCT01878526

Phase 3 Completed 80 enrolled Khon Kaen University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus omeprazole in combination with domperidone on the severity of reflux symptoms in omeprazole resistant GERD in SSc, and to compare the efficacy of omeprazole in combination with algycon versus omeprazole in combination with domperidone on the frequency of symptoms in omeprazole- resistant GERD in SSc.

Timeline

Start
2013-06
Primary completion
2015-08
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alginic acid Other / unclassified Oral
Subject Domperidone Unknown 10 mg Oral